Drug Trial Radar · NCT06734832
Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)
Last checked: Nov 20, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8,000
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Nov 30, 2025
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 71 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blind, controlled Phase III clinical trial aims to evaluate the efficacy, safety, and immunogenicity of the bivalent enterovirus-inactivated vaccine (Vero cell) in healthy children aged 6 to 71 months. The main questions it aims to answer are: * The primary vaccine efficacy of the investigational vaccine against Hand, Foot, and Mouth Disease(HFMD) caused by CA16 infection compared to the control vaccine. * The neutralizing antibody levels against EV71 in the trial group are non-inferior to those in the control group after two doses of vaccination. Researchers will compare the bivalent enterovirus-inactivated vaccine (Vero cell) to the EV71-inactivated vaccine (Vero cell) to prevent HFMD and Herpangina(HA). Participants will be randomly assigned to the trial group and the control group in a 1:1 ratio to receive two doses of the investigational vaccine or the control EV71 vaccine, with a one-month interval between doses.
Conditions
- Hand, Foot, and Mouth Disease(HFMD)
Interventions
bivalent enterovirus vaccine (Vero cell), inactivatedBiological
Two doses are administered with a one-month interval between each dose.
Enterovirus Type 71 Vaccine (Vero Cell), InactivatedBiological
Two doses are administered with a one-month interval between each dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the primary vaccine efficacy of the trial vaccine against HFMD caused by CA16 infection compared to the control vaccine.Time frame: 1 year
- Evaluate whether the neutralizing antibody levels against EV71 in the trial group are non-inferior to those in the control group after two doses of vaccination.Time frame: 60 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Fujian Provincial Center for Disease Control and Prevention
Fujian, China · Recruiting
Guangdong Provincial Center for Disease Control and Prevention
Guangdong, China · Recruiting
Hubei Provincial Center for Disease Control and Prevention
Hubei, China · Recruiting
Anhui Provincial Center for Disease Control and Prevention
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.